Sphera Funds Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Sphera Funds Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-681,210	Closed	-$2.52M	–	163
2017 Q4	$2.52M	Hold	681,210	–	–	0.3%	81
2017 Q3	$2.79M	Hold	681,210	–	–	0.4%	64
2017 Q2	$2.53M	Buy	681,210 +100,000	+17%	+$397K	0.43%	72
2017 Q1	$2.41M	Buy	+581,210	New	+$2.44M	0.47%	62
2015 Q1	–	Sell	-71,333	Closed	-$813K	–	177
2014 Q4	$813K	Hold	71,333	–	–	0.14%	113
2014 Q3	$822K	Sell	71,333 -51,723	-42%	-$790K	0.1%	113
2014 Q2	$2.39M	Hold	123,056	–	–	0.59%	43
2014 Q1	$2.21M	Sell	123,056 -1,667	-1%	-$27.4K	0.5%	42
2013 Q4	$1.32M	Buy	+124,723	New	+$1.39M	0.37%	65

Sphera Funds Management's CASC Position: Q1 2018 in Review

Sphera Funds Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 681,210 shares — an estimated $2.52M sold.

Sphera Funds Management first reported a position in CASC in Q4 2013 and held it in 9 quarters. The position peaked at $2.79M in Q3 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Sphera Funds Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Sphera Funds Management sold 681,210 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2.52M.
Sphera Funds Management first reported a position in Cascadian Therapeutics, Inc. in Q4 2013 and held it in 9 quarters.
Sphera Funds Management's Cascadian Therapeutics, Inc. position peaked at $2.79M in Q3 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.